Takis

Takis participated in the Festival of Biologics 2024, from October 15th to 17th at Messe Basel, Switzerland! This prestigious #event brought together top professionals from the #biologics industry, covering the entire value chain—from discovery and development to clinical trials, manufacturing, and market access. Our Takis members, Alessia Muzi and Giuseppe Roscilli joined a round table discussion on “Bispecific #antibody engineering: challenges and strategies,” where they shared their #insights and #expertise in this groundbreaking field. Events like the Festival of Biologics provide a vital platform to bridge the gap between academia and industry, driving the latest advancements in biologics. We look forward to the new #collaborations and ideas generated to events like this as we continue our mission in biomedical #research!

On October 25th, Takis had the honor of participating among a selected group of Italian companies in the “Italy-China Workshop: Globalization, Borders, and Identity”! The #event has been organized by the Camera di Commercio Roma and the Foundation for International Studies and Geopolitics, in collaboration with the Embassy of the People's Republic of China in Italy. It brought together leading companies from #Italy and #China in various industrial sectors, including the #Pharmaceutical one. It was a privilege for Takis to be part of this event, exploring potential collaborations and opportunities in the Chinese market. We look forward to building meaningful partnerships and expanding our global network! Tecnopolo Roma

At Takis, we put our heart and soul into our mission… and seeing that 7,000 people #follow our efforts here on this platform is an incredible honor. We are truly grateful for the support of each and every one of you. Your #engagement and interest drive us forward as we continue to innovate in the fields of #biotechnology, #cancer #research, and epidemic preparedness. Thank you for being part of this incredible journey on #LinkedIn! 7.000 Grazie!

From October 2nd to 4th, Takis had the opportunity to participate in the 30th National Congress of AISAL, the Italian Association for Laboratory Animal Science! The congress took place at the CNR conference hall and, in its 30th edition, addressed the theme of complementarity and integration of methodologies, regulations, and expertise in preclinical research involving the use of #laboratoryanimals. Representing Takis were our Animal Welfare Officer, Fabiana Fosca Ferrara, and researcher Manuela Cappelletti. During the event, we had the chance to attend notable presentations and speeches, including those by Dr. Maylander, DGSA from the Ministero della Salute, and Dr. Panzini from the Istituto Superiore di Sanità, who discussed the challenges faced by auditors, as well as Dr. Limatola from CNPA, who spoke about the interactions between CNPA and OPBA. We would also like to mention Dr. D'Amore from the ISS, a prominent figure in our field, who served as a moderator for one of the conference sessions. Additionally, we had the pleasure of meeting veterinarian VINCENZO PENTELLA, a valuable ally in scientific research. This autumn has been filled with significant scientific meetings, offering unique opportunities for discussion, learning, and strengthening our expertise in such a delicate and crucial area as preclinical research. We look forward to continuing our participation in high-caliber events like this, reinforcing our commitment to advancing biomedical research.

Have you not been able to attend the inauguration of our new BSL-3? Or you simply want to live it all over again? Enjoy this throwback video! The event brought together key figures from the biotech and political sectors, all emphasizing one essential point: this lab is a crucial step forward for scientific research and epidemic preparedness in Italy. In this video you can listen to small extracts from the speeches and enjoy the event as if you were there! The BLS-3 module, which is already operational, represents a fundamental step towards creating innovative "Made in Italy" therapies. We thank all the participants and speakers, who contributed to the success of the BSL-3 inauguration: Giuliano Peretti, ANASPI General Manager; Giuseppe Biazzo, President of Unindustria Roma - Frosinone - Latina - Rieti - Viterbo; Giancarlo De Matthaeis, President of Labozeta SpA; Prof. Rino Rappuoli, Siena Biotecnopolo Scientific Director; Lorenzo Tagliavanti, President of the Camera di Commercio Roma; On. Edy Palazzi, Councilor of the Regione Lazio; On. Luciano Ciocchetti, Deputy of the Camera dei deputati; and Sen. Marco Silvestroni, Senator of the Senato della Repubblica. We thank of course our COO Emanuele Marra, our CTO Giuseppe Roscilli and CEO Luigi Aurisicchio, and all Takis staff for all the dedication in making this incredible step forward possible. At Takis, we don’t aim to be a big company at all costs; we aim to do great research, and this module will let us do exactly that! Unindustria Roma - Frosinone - Latina - Rieti - Viterbo | Assobiotec

The inauguration of Takis' biosafety level 3 (BSL-3) module was not just a ceremony: it marked the culmination of months of hard work, dedication, and cutting-edge innovation. Our team worked relentlessly, from scientists to engineers, to bring this project to life. This advanced module is now a hub where innovation meets the highest safety standards, enabling us to tackle dangerous pathogens like SARS-CoV-2, Mycobacterium tuberculosis, Dengue, Zika and others. But this is not a “destination”. It is the beginning of a journey that will accelerate drug development in Italy and improve the epidemic preparedness of our country. If you want to test a new drug or run a research activity on a pathogen that requires level-3 security… send us a message! The available slots for the coming months are getting filled quickly! #biosafety #innovation #safety #hardwork #drugdevelopment #research

We are pleased to announce the official inauguration of the first biosafety level 3 laboratory module (#BSL3) in #Italy! 🇮🇹 This is not only a significant achievement but also a starting point for the future of the #biotech sector. The module, which is already operational, allows for the study of pathogens such as SARS-CoV-2, Dengue, Zika, and tuberculosis, and represents a fundamental step towards creating innovative "Made in Italy" therapies. "The module will be a driver of knowledge and #innovation for the sector" said our CEO, Luigi Aurisicchio. "This facility enables us to push the boundaries of #research, paving the way for new #vaccines and treatments that will strengthen both local and global #health resilience" added our CTO Giuseppe Roscilli. The BSL3 module enables the identification of molecular targets suitable for designing vaccines and other drugs capable of fighting dangerous #diseases for humans, testing their effectiveness both in vitro and in vivo. Our company's broader goal is to build a network of regional, national, and international partners to collaborate with, in order to develop new drugs quickly and improve the epidemic preparedness of our country and the whole world. For this reason, we are especially pleased to have had with us the representatives from various important organizations and institutions, including Dr. Giuseppe Biazzo, the new President of Unindustria Roma - Frosinone - Latina - Rieti - Viterbo, Prof. Rino Rappuoli, who gave an enlightening speech on the future of diseases and their economic and social impact, Giancarlo De Matthaeis, President of Labozeta SpA, a key partner in the realization of the module together with Teco SRL, Lorenzo Tagliavanti, President of the Camera di Commercio Roma, On. Edy Palazzi, Councilor of the Regione Lazio, On. Luciano Ciocchetti, Deputy of the Camera dei deputati, and Sen. Marco Silvestroni, Senator of the Senato della Repubblica. We conclude with the words of our COO, Emanuele Marra: "It has been a challenging journey where our resilience was put to the test. Building this module was a true feat. But we are convinced that 'Made in Italy' is much more than just the origin of certain ingredients. It is the ability of our people to develop the therapies of the future. At Takis, we don’t aim to be a big company at all costs; we aim to do great #research, and this module will let us do exactly that! Assobiotec |

Lunedì 7 Ottobre alle 10:00 si terrà l'inaugurazione ufficiale del nostro #biomodulo BSL-3! 🎯 Il biomodulo è già operativo presso la nostra sede di Castel Romano, ma Lunedì sarà l'occasione perfetta per avviare ufficialmente i lavori e condividerne tutte le potenzialità. L'evento sarà alla presenza delle autorità pubbliche. Nella locandina qui sotto trovate i dettagli. Se volete partecipare, mandateci un'email a info@takisbiotech.it

From the 23rd to the 27th of September we participated at the 7th edition of the Innovative Approaches for Antiviral Agents (IAAASS) in Pula, Cagliari Province. This exciting event took place in the Sardegna Ricerche Research Park and in the Hotel Flamingo, Santa Margherita di Pula, located on the south tip of Sardinia. It was an informal and interactive meeting that aimed at engaging early-stage researchers in reviewing the most advanced techniques for the identification of novel and clinically significant #antiviral effective agents. Our researcher Emanuela D’Acunto, had the opportunity to present to the young scientists her antiviral agents' assay and to discuss with experts in the field. She also joined the round table in the ADVISE in which Sardegna Ricerche sponsored the open session “Public-private synergies in viral research”. It was a special experience that allowed us to share our knowledge and scientific expertise for the advancement of science. We thank the Organizing Committee of IAAASS and all the participants. We hope for a great future in the scientific #research world for all of you!

At Takis, we offer a complete service for the generation, optimization, and validation of #ELISA kits, designed to meet the highest standards of precision and reliability. Our process involves a detailed and rigorous approach to ensure your assays deliver accurate, reproducible results across a wide range of #applications. Key steps in our process include: - Definition of Reagents, - Preliminary Assessment, - Optimization, - Assay Parameter Establishment, - Matrix Effect Evaluation, - Reproducibility Testing, - Development of SOPs and Protocols. With Takis' advanced ELISA kit services, we support your #research with cutting-edge, validated tools tailored to your specific needs. Contact us here on LinkedIn to learn more!